

CURRICULUM VITAE

ORNELLA RIMOLDI MD FACC FAHA

May 2019

ORNELLA ELETTRA RIMOLDI MD, FACC, FAHA

PERSONAL DETAILS

Name: Ornella Elettra Rimoldi
Nationality: Italian
Address : Via Saini 37
28046 Meina (Novara)
Italy
e-mail : rimoldi.ornella@hsr.it
Telephone: +39 3313086575

GENERAL EDUCATION

High School Diploma Maturità Scientifica 58/60, 1973

Pre-clinical Training: Medical Doctor, Magna cum Laude April 1981,
University of Milan Medical School

Post graduate Training: Specialisation in Cardiology(CCT) 70/70 cum Laude
1983, University of Milan
Specialisation (CCT) in Clinical Pharmacology 70/70
1985-1989, University of Milan

APPOINTMENTS

July 2017 Italian National Scientific Board Endorsement as
Associate Professor, section 06/D1 ;

May 2013 to date Honorary Professor Specialty School Cardiovascular
Diseases Università Vita Salute San Raffaele, Milan,
Italy

Dec 2017 to date Clinical Senior Scientist (Primo Ricercatore) Istituto di
Bioimmagini e Fisica Molecolare (IBFM) C.N.R. Segrate
Italy.

Oct 2010 Dec 2017 Clinical Scientist (Ricercatore) Istituto di Bioimmagini e
Fisica Molecolare (IBFM) C.N.R. Milan Italy.

April 2009 July 2010 Honorary Consultant Cardiac Imaging Hammersmith
Hospital Imperial College Healthcare NHS Trust

July 2006 Dec 2008 Honorary Associate Professor New York Medical College

January 2000 July 2010 Honorary Senior Lecturer NHLI, Imperial College

January 2003 July 2010 Honorary Clinical Senior Scientist CSC, MRC

May 2001 Oct 2010 Honorary Investigator National Research Council (CNR)
IFC Pisa

Mar 1996 - Dec 2002 Honorary Clinician Scientist, MRC Cyclotron Unit

Oct 1995- Feb 1996 Visiting Lecturer, Harvard Medical School (New
England Regional Primate Research Center)

1988-2001 Investigator National Research Council (CNR) Centre for
Cardiovascular Research, Milan

1979-1988 Research Fellow at the Cardiovascular Research Unit,
University of Milan

PROFESSIONAL SOCIETES

Fellow of the American College of Cardiology 2000-2010

Member of the Working Group of Nuclear Cardiology of the European Society of
Cardiology, EACVI

Member of the Councils on Basic Cardiovascular Science and Clinical Cardiology
of the American Heart Association. Membership N 100001574421

Fellow of the American Heart Association

Member of the International Society of Cardiovascular Magnetic Resonance and
British Society of Cardiac Magnetic Resonance

Chair working group “Coronary microcirculation“ Societa’ Italiana di Cardiologia
(2014-2016)

Member of the Editorial Board of the European Heart Journal Cardiovascular
Imaging (ISSN:2047-2412), Circulation Cardiovascular Imaging (ISSN: 1942-
0080), American Journal of Nuclear Medicine and Molecular Imaging (AJNMMI)
(ISSN: 2160-8407).

Deputy Editor International Journal of Cardiology (2016-todate)

Currently a referee for the following journals:

Journal of American College of Cardiology since 2000

Cardiovascular Research since 2000

European Heart Journal since 2004

Journal of Nuclear Medicine since 2003

Eur J Nucl Med Mol Imaging since 2005

American Journal of Cardiology since 2005

Journal of Cardiovascular Magnetic Resonance since 2006

Member of the Abstract review Committee for ESC Congress since 2002.

Member of the Abstract review Committee for AHA since 2004.

Chair person at the Congress of the European Society of Cardiology since 2002.

Chair person at the America Heart Association Congress since 2004.

Named expert REPRIS: Register of Expert Peer Reviewers for Italian Scientific Evaluation

RESEARCH TRAINING AND RELEVANT EXPERIENCE

Istituto di Ricerche Cardiovascolari (Cardiovascular Research Unit), University of Milan, Italy (1977-95)

My research training began at the Istituto di Ricerche Cardiovascolari, University of Milan, directed by Prof. A. Zanchetti.

After graduating, I continued to be involved in studies on the role of reflex sympathetic activation during myocardial ischaemia or due to direct cardiac stimulation by means of intracoronary bradykinin (4).

In collaboration with the Department of Systems Analysis of the Faculty of Engineering, University of Milan, I was involved in studies on the theoretical aspects of the study of heart rate variability. I carried out the fundamental experiments for the definition of the physiological interpretation of heart rate variability, under the guidance of Professor Massimo Pagani. The results have been published extensively in medical (6,10,11,12,15,17,20,41) and engineering (9,10,16,19,22,46) journals. The paper published in Circulation Research in 1986 (6) is generally considered one of the most valuable contributions in the field. My experimental activity of also encompassed the study of the physiological mechanisms underlying the direct and reflex action on the cardiovascular system of different drugs, including calcium antagonists (7), prostaglandins (8, 14), ACE inhibitors (20) and thromboxane receptor blockers (18).

Harvard School of Medicine (1993-1995)

Between 1993 and 1995, I was involved in a bilateral project between the Italian National Research Council in Milan and Harvard School of Medicine (New England Regional Primate Research Center, directed by Prof. SF Vatner) on the study of the early alterations of neural control of the cardiovascular system in an animal model of pacing-induced heart failure.

PET Cardiology, MRC Cyclotron Unit and Clinical Sciences Centre, Hammersmith Hospital, London (1996 to 2010)

In 1996 I started to cooperate with the PET Cardiology Group directed by Prof P Camici at the MRC Cyclotron Unit Clinical Sciences Centre at Hammersmith Hospital.

My main task have included:

- a)** To set up and manage a laboratory for the study of cardiac pathophysiology in large animal models;
- b)** To be in charge of the project for the investigation of transmural myocardial blood flow distribution in patients with coronary artery disease and those with left ventricular hypertrophy which included the validation of the new prototype CTI EXACT 3D PET scanner.

Experimental studies.

1) Validation of the EXACT 3D PET scanner for the measurement of myocardial blood flow with oxygen-15 labelled water. This project has involved extensive collaboration with the Methodology Section of the Cyclotron Unit including physicists and radiochemists. (47). Further experimental validation of the EXACT3D scanner in a porcine model of coronary stenosis and demand ischemia(62). These studies provided the experimental background to human studies aiming at investigating the transmural distribution of myocardial blood flow in myocardial hypertrophy (44, 53,74) and hibernation.

2) Set up of an animal model of repetitive stunning to complement the studies by Prof Camici on patients with heart failure and hibernating myocardium (28, 43, 48). The hypothesis that hibernating myocardium could be the result of multiple episodes of ischemia has been addressed in several reviews (29, 50, 52 ,58, 69, 72) and quoted in Braunwald, Zipes, Libby Eds “Heart Disease” 6th Edition ref 238 p1107.

3) Validation in a porcine infarct model of a new method for the quantification of infarct size This project involved the development of new dedicated software and is carried out in collaboration with the University of Muenster, Germany (45).

4) Development and validation of a prazosin derivative GB-67 a new selective ligand to image cardiac α_1 -receptors in humans (38, 40, 70).

Clinical Studies.

1) Transmural distribution of myocardial blood flow in patients with left ventricular hypertrophy secondary to aortic stenosis or arterial hypertension. In patients with LVH there is a significant reduction of coronary flow reserve mainly in the subendocardium that is correlated to the valve area (44, 53, 63, 67,73).

2) Study on transmural distribution of myocardial blood flow in normal subjects, and patients with CAD. This study addresses the topic of quantification and distribution pattern of resting coronary blood flow in hibernating myocardium (69).

3) I have continued to pursue my interest on the influence of the autonomic nervous system on coronary microcirculatory function.

Effect of alpha blocking agents after percutaneous transluminal coronary angioplasty (PTCA) in patients with coronary artery disease (37). The topic of alpha adrenergic control of the coronary circulation was addressed in a comprehensive review (39) quoted in Braunwald, Zipes, Libby Eds “Heart Disease” 6th Edition ref 142a page 1099.

I co-investigated the role of neural Nitric Oxide in the modulation of coronary flow reserve in healthy volunteers and in patients with denervated hearts after transplant (56, 66). As a corollary I co-authored studies in patients with diabetic neuropathy (49) and Brugada syndrome (59). The measurement of down-

regulation of β -adrenergic receptor (^{11}C -CGP) early after myocardial infarction has proven a predictive factor for the incidence of heart failure in the long term (78).

4) Effects of novel surgical procedures in patients with end stage coronary artery disease or cardiomyopathy. In collaboration with Papworth Hospital, Cambridge (32). In collaboration with Harefield Campus and Sir M. Yacoub I co-authored a study on the effect of left ventricular assist device (LVAD) on myocardial blood flow in patients with end stage dilated cardiomyopathy(60).

5) Validation of the method for the quantification of infarct size [which follows the relative validation in the animal model (see point 4 above)] in explanted hearts of patients undergoing cardiac transplantation (45).

6) At the same time I was fully trained in cardiovascular magnetic resonance and co-operated with Prof. D. Pennell and his group (Dr. S. Prasad, Dr. K Rajappan) to investigate algorithms employing Fermi deconvolution to measure transmural myocardial blood flow in hibernating myocardium(54,64,68) and aortic stenosis (43).

7) In collaboration with Prof. S. Neubauer group in Oxford a feasibility study comparing a new technique blood oxygenation level-dependent (BOLD) at 3 Tesla and PET perfusion and coronary flow reserve measurements was carried out in patients with coronary artery disease (CAD) and normal volunteers (74,82). In this study it was demonstrated that T2-prepared SSFP 3T BOLD imaging is feasible in the clinical setting and has good agreement with PET perfusion parameters for the detection of myocardial ischaemia.(92)

8) In the last period of activity in London I lead the project to validate a quantitative methodology for imaging large vessel inflammation with [^{11}C]-(*R*)-PK11195 deriving both plasma and image input functions in patients with active vasculitides (75,78,83). The volume of distribution of [^{11}C]-(*R*)-PK11195 resulting from quantitative kinetic analysis correlated with the performance of the standardized uptake value (SUV) to discriminate active and non-active vasculitides (81,83,85). These studies were the groundwork to the use of [^{11}C]-(*R*)-PK11195 as a tracer to detect carotid intraplaque inflammation in vivo with PET/CTA.. Patients with a recent ischaemic event had ipsilateral plaques with lower CT attenuation and increased (^{11}C)-PK11195 uptake (88). A collaboration is ongoing with Prof. P.Libby (Mallinckrodt Professor of Medicine, Brigham and Women Hospital, Harvard Medical School) (90).

C.N.R. I.B.F.M.

I moved from I.F.C. Pisa to I.B.F.M. Segrate, I continued my collaboration with Prof. P. Camici and set up in San Raffaele Hospital the study of carotid plaques with the radiotracer [^{11}C]-(*R*)-PK11195 (88,93, 105,109) and their correlation with white matter brain lesions and circulating inflammatory cells.

I continued the studies of myocardial perfusion with PET and CMR in patients with coronary artery disease and left ventricular hypertrophy and wrote several reviews on this topic (89, 99, 103, 106, 110).

I initiated a collaboration with Dr. M. Frigerio and Prof. C. Giannattasio at the Cardiac Magnetic Resonance facilities Niguarda Hospital to test the performance of Work in Progress cardiac magnetic resonance sequences designed by Siemens AG Erlangen in patients who underwent heart transplant. I am leading the project of the study to measure and validate the in-vivo detection of diffuse fibrosis and inflammation in the w heart in transplanted patients and volunteers by means of T1 and T2 mapping techniques. The study entails monitoring over time interstitial fibrosis and its prospective value for the development of morbidity and mortality (91,104).

International collaborations:

I continued the collaboration with Prof. S. Neubauer (Oxford University) and Prof. C. Kramer (University of Virginia) participating into the International multicentric study HCMR in patients with hypertrophic cardiomyopathy who will be studied with cardiac magnetic resonance. This study aims at changing the existing paradigm in HCM by improving risk stratification, establishing risk predictors, identifying surrogate endpoints to monitor treatment response. The first step of enrolling was concluded end of 2018 (manuscript submitted)

Ongoing collaboration with Prof. M. Di Carli and Dr. S. Dorbala (Brigham & Women's Hospital, Harvard Medical School Boston, MA) for studies on microcirculatory dysfunction with particular interest in the effects of gender on cardiac outcomes (97, 102, 107)

Collaboration with Prof. H. Shimokawa (Tohoku University Sendai, Japan) The registry aims to elucidate the risk factors, clinical features, diagnostic methods, treatments and prognosis of patients with Microvascular Angina in the medium term. The enrolment was completed in December 2018 and 837 patients have been enrolled in 15 countries.

Clinical competence level

In Italy I have been trained in non-invasive cardiology (echocardiography, stress SPECT) during my internship.

Since I have started my collaboration in the United Kingdom I have worked with PET(positron emission tomography). Over the years I have attained and maintained a high level of cognitive and technical skill in cardiac imaging according to ACCF AHA Clinical competence Statement on cardiac imaging (Budoff et al. Circulation , 2005:112:598-617)

Cardiac PET level of 3 of clinical competence. More than 300 scan completed and interpreted. Dr Rimoldi is a renowned expert in the field and has written two reviews on diagnosis and treatment of myocardial hibernation (69, 79).

Cardiac Magnetic Resonance level 3 of clinical competence Royal Brompton Hospital, London UK(>800 examined and interpreted, including MRA and adult congenital GUCH).

Cardiac Computed Tomography level 2 in 2005. 100 contrast examination (Universitat Spital Zurich). Attended 4th cardiovascular magnetic resonance and computed tomography state of the art Washington DC June 2006.

TUTORIAL ACTIVITIES

I helped to supervise the work of a number of higher degree students providing them with theoretical and practical teaching:

- Dr C. Baker (PhD student, ICSM): set up of the experimental model of stunning in anaesthetised pigs (28, 43, 48, 51).
- Dr P Chareonthaitawee (visiting fellow from Mayo Clinic, Rochester USA): training in PET techniques to carry out the study “Assessment of infarct size in patients with heart failure”. (42,45)
- Dr K Rajappan (MD student, ICSM): teaching, experimental design, data acquisition on the EXACT3D scanner and data handling for the study “Investigation of changes in coronary reserve and ECG during progression of left ventricular mass before and after aortic valve replacement”.(44, 52)
- Edward Barnes (MD student, ICSM): teaching, experimental design, data acquisition and handling for the study “Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia” (36). This study is the clinical complement to the studies on myocardial stunning in pigs.
- K. Schaefer (PhD student visiting from Muenster University, Germany): guidance on physiological mechanisms to develop original software for the measurement of infarct size with PET (42). Validation of the measurement of myocardial blood flow in 3D (47)
- Dr PA Kaufmann (PhD visiting from University of Zurich, Switzerland) tutoring in experimental design and pathophysiological implications for validation studies (33) and autonomic control of coronary circulation (56)

- L. Livieratos (PhD student, University of Surrey): Technical and physiological advice to set-up monitoring of respiratory movements in order to implement gating facilities on the scanner Exact 3D.

- Dr. R Jagathesan (MD student, ICSM) experimental design, data acquisition and handling for the study “Assessment of the long term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease”(61).

- Dr. Paul Bhamra-Ariza (MD student, ICSM 2010) co-supervisor for the study “Non invasive measurement of absolute myocardial perfusion in humans: a comparison between Positron Emission Tomography and Cardiac Magnetic Resonance Imaging” stud in co-operation with Oxford University Prof. S. Neubauer and Harvard University Prof M. Herold-Jerosh.

- Dr. Lara Tondi (MBBS Bachelor of Medicine with Hon.2014) co-supervisor for the study “Effects of oral administration of Ivabradine (7.5 mg BID) on post-ischaemic stunning induced by exercise stress in patients with CAD and exercise inducible ischaemia”.

- Dr. Marco Spartera (CCT cardiology July 2017) co-supervisor with Prof. PG Camici Universita' Vita Salute, Prof. V. Ferreira Radcliffe Hospital, Oxford UK for the thesis "Regadenoson Stress TI mapping Can distinguish between ischaemic, infarcted, remote and normal Myocardium without the use of Gadolinium contrast medium"

MANAGEMENT and ADMINISTRATIVE ACTIVITIES

Consultancy, Bayer AG (Milan) 1992-1996

Bayer AG as a Specialist clinical pharmacologist I am knowledgeable of the European Union Clinical Trial Directive, GCP and GMP. I supervised the monitoring of clinical trials investigating the effect of Ca⁺⁺-antagonists in coronary artery disease, and wrote final reports of clinical trials for regulatory requirements.

Clinical research governance, experimental design combining the requirement for controlled studies. Risk assessment to monitor and minimise the risks to patients and staff and safety issues involved in the appropriate use of ionising radiation. Competence on the legal basis for RECs (Research Ethic Committee) applications for REC approval of clinical single centre or multicentre studies. Clinical audits are conducted regular basis to assess scanning practice against standard guidelines and set local standards and SOPs.

GRANTS

Co-principal investigator British Heart Foundation (1998) in collaboration with Prof. M Noble (Imperial College, London) and Prof PG Camici (PG/97034): “PET studies of coronary blood flow, flow reserve and metabolic and endothelial control of flow in the chronically denervated dog heart”.
£ 80,533

Co-principal investigator grant Knoll AG (1999): PI Prof PG Camici: “Effect of anti-hypertensive treatment with verapamil SR-240 mg and amlodipine 5 mg on the coronary vasodilator reserve and the transmural distribution of myocardial blood flow in patients with left ventricular hypertrophy and arterial hypertension”.
£ 217,000

Principal investigator grant CV Therapeutics (2002): Co-PI Dr. L. Belardinelli “Assessment of efficacy of adenosine A₁ receptor agonist CVT510 in prevention and reduction of ischemia/reperfusion damage” £ 43,000

Principal Investigator MRC Stem Cell initiative (2003) strategic grant in stem cell research collaborators New York Medical College Prof. P. Anversa, Dr. A. Leri, Dr. J. Kajstura “Stem cell plasticity in the heart after myocardial infarction”£ 258,933

Partner BHF Cardiovascular Initiative 2005 “BHF grant for improvement of large animal facilities: equipment for hemodynamic measurement, angiography, ultrasound, intravenous ultrasound, intra-coronary pressure and optical coherence tomography”. P.I .Prof. D. Haskard in collaboration with NHLI division. ~£ 1,000,000

Co-applicant MIUR (Ministry of University and Research of Italy) PRIN project grant 2010 *Relationship between morpho-functional characterization of carotid*

plaque and cerebral damage load a multimodal non invasive study of the plaque.
P.I. Dr. Enrico Ammirati €229,000.

Co-applicant MIUR (Ministry of University and Research of Italy) Network project grant “*Mechanisms And Treatment Of Coronary Microvascular Dysfunction In Patients With Genetic Or Secondary Left Ventricular Hypertrophy*” € 1.301.133,32 in collaboration Università Vita Salute San Raffaele Milan, University of Florence and University of Rome.

Italian Principal Investigator CNR bilateral grant Italy-Japan Japanese PI Prof. H Shimokawa (Tohoku, University Sendai). Accordo di cooperazione scientifica CNR/JSPS (Japan Society for the Promotion of Science) – Giappone Biennio 2016/17 “*International Prospective Registry for the Study of Patients with Microvascular Angina*” €8,000.

PUBLICATIONS

H INDEX ISI WEB OF SCIENCE : 40

Papers in peer reviewed journals

1. Pagani M, Pizzinelli P, Furlan R, Guzzetti S, **Rimoldi O**, Malliani A: *A sympathetic hypertensive reflex from the heart of conscious dogs*. *Cli Sci* 1981;61:11s-183s
2. Pagani M, Pizzinelli P, Furlan R, Guzzetti S, **Rimoldi O**, Malliani A: *Riflesso pressorio a partenza dal cuore nel cane non anestetizzato*. *Boll Soc Ital Cardiol* 1981, 26:1071-1075
3. Pagani, M, Lombardi F, Guzzetti S, Sandrone G, **Rimoldi O**, Malfatto G., Cerutti S, Malliani A: *Power spectral density of heart rate variability as an index of sympatho-vagal interaction in normal and hypertensive subjects*. *J Hypertens Suppl*, 1984. 2(3): p. S383-5.
4. Pagani M, Pizzinelli P, Furlan F, Guzzetti S, **Rimoldi O**, Sandrone G, Malliani A. *Analysis of the pressor sympathetic reflex produced by intracoronary injections of bradykinin in conscious dogs*. *Circ Res* 1985;56:175-183.
5. Pagani M, **Rimoldi O**. *Neural control of vasomotor tone of large coronary arteries*. *Can. J. Cardiol. Suppl A* 1986: 32A-39A.
6. Pagani M, Lombardi F, Guzzetti S, **Rimoldi O**, Furlan R, Pizzinelli, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, Turiel M, Baselli G, Cerutti S, Malliani A. *Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog*. *Circ Res* 1986, 58:178-193.
7. Pagani M, Pizzinelli P, Guzzetti S, Furlan R, **Rimoldi O**, Sandrone G, *Effects of verapamil, nifedipine, and dilazep on left ventricular relaxation in the conscious dog*. *Cardiovasc Res* 1987;XXI(1):55-64.
8. **Rimoldi O**, Pierini S, Sandrone G, Songini MG, Pagani M. *Abolizione mediante Iloprost della tachicardia prodotta dall'ischemia miocardica transitoria nel cane non anestetizzato*. *Cardiologia*, 1987;32(1):77-80.
9. Baselli G, Cerutti S, Livraghi M., Meneghini C, Pagani M, **Rimoldi O**. *Causal relationship between heart rate and arterial blood pressure variability signals*. *Med. & Biol. Eng. & Comput*, 1988 26:374-378.
10. Cerutti S, Alberti M, Baselli G, **Rimoldi O**, Malliani A, Merri M, Pagani M. *Automatic assesement of the interaction between respiration and heart rate variability signal*. *Med Prog Technol*, 1988; 14:7-19.
11. **Rimoldi O**, Pagani M, Pagani MR Baselli G, Malliani A. *Sympathetic activation during treadmill exercise in the conscious dog: assessment with spectral analysis of heart period and systolic pressure variabilities*. *J. Auton. Nerv. Sys.* 1990;30:S129-S132.
12. **Rimoldi O**, Pierini S, Ferrari A, Cerutti S, Pagani M, Malliani A. *Analysis of short-term oscillations of R-R and arterial pressure in conscious dogs*. *Am J Physiol* 1990;258:H967-H976.

13. Pagani M, **Rimoldi O**, Pizzinelli P, Furlan R, Crivellaro W, Liberati D, Cerutti S, Malliani A: *Assessment of the neural control of the circulation during psychological stress*. J Auton Nerv Syst 1991;35:33-42.
14. **Rimoldi O**, Pierini S, Pagani MR, Pagani M. *Reduced cardiovascular sympathetic excitatory responses during iloprost infusion in conscious dogs*. Cardiovasc Res 1991; 25:793-801.
15. **Rimoldi O**, Furlan R, Pagani MR, Piazza S, Guazzi M, Pagani M, Malliani A. *Analysis of neural mechanisms accompanying different intensities of dynamic exercise*. Chest 1992;101 Italian Suppl:226S-230S.
16. **Rimoldi O**, Pagani MR, Piazza S, Merri M, Pagani M, Malliani A. *Assessment of beat-by-beat respiratory influence on cardiovascular parameters*. J Ambulat Monitoring 1992;5:65-77.
17. Pagani M, **Rimoldi O**, Malliani A. *Low-frequency components of cardiovascular variability as markers of sympathetic modulation*. TiPS 1992; 13: 50-54.
18. Salvati P, Dho L, Ukmar G, Vaga L, **Rimoldi O**, Patrono C. *A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis*. JPET 1993,269,(1):238-245.
19. Baselli G, Cerutti S, Badilini F, Biancardi L, Porta A, Pagani M, Lombardi F, **Rimoldi O**, Furlan R, Malliani A. *Model for the assessment of heart period and arterial pressure variability interactions and of respiration influences*. Med. & Biol. Eng. and Comput., 1994; 32:143-52.
20. **Rimoldi O**, Pagani MR, Piazza S, Pagani M, Malliani A *Restraining effects of captopril on sympathetic excitatory responses in dogs: a spectral analysis approach*. Am. J. Physiol., 1994;267:H1608-H1618.
21. Pagani, M, Lucini D, **Rimoldi O**, Furlan R, Piazza S, Porta S, Malliani A: *Low and high frequency components of blood pressure variability*. Ann N Y Acad Sci, 1996. **783**: p. 10-23.
22. Baselli G, Porta A, **Rimoldi O**, Pagani M, Cerutti S *Spectral decomposition in multi-channel recordings based on multi-variate parametric identification*, IEEE Trans Biomed Eng, 1997; 44:1092-1101.
23. Camici PG, **Rimoldi O**; *La circolazione coronarica nell'iperteso: possibilità terapeutiche*. Cardiologia 1997; 42: 75-78.
24. Camici PG, **Rimoldi O**: *Resting myocardial blood flow in patients with hibernating myocardium quantified by positron emission tomography*. Basic Res Cardiol 1997; 92: 6-8.
25. Boyd H, Rosen SD, **Rimoldi O**, Cunningham V, Camici PG: *Normal values for left ventricular volumes obtained using gated PET*. G Ital Cardiol 1998; 28:1207-1214.
26. Camici PG, **Rimoldi O**: *Blood flow in myocardial hibernation*. Current Opinion in Cardiology 1998; 13: 409-414.
27. Choudhury L, Elliott P, **Rimoldi O**, Ryan M, Lammertsma AA, H. Boyd, McKenna WJ, Camici PG; *Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy during stress: effect of high-dose verapamil therapy*. Basic Res Cardiol. 1999;94: 49-59.
28. Baker CSR, **Rimoldi O**, Camici PG, Barnes E, Chacon MR, Huehns TY, Haskard DO, Polak JM, Hall RJC: *Repetitive myocardial stunning in pigs is associated with an increase in expression of inducible and constitutive nitric oxide synthases*. Cardiovasc Res 1999; 43: 685-697.

29. Camici P.G., **Rimoldi O**. *Myocardial hibernation vs repetitive stunning in patients*. *Cardiology in Review*, 1999; 7: 39-43.
30. Chareonthaitawee P, Barnes E, **Rimoldi O**, Camici PG, Burke MM, Khaghani A. *Viability in chronic ischaemic cardiomyopathy: need for timely revascularisation*. *Eur J Nucl Med*. 1999 Nov;26(11):1521-2.
31. Camici PG, **Rimoldi O**: *The coronary microcirculation in left ventricular hypertrophy*. *Cardiologia*, 1999; 44 (Suppl 2):783-786.
32. **Rimoldi O**, Burns SM, Rosen SD, Wistow TE, Schofield PM, Taylor G, Camici PG: *Measurement of myocardial blood flow with positron emission tomography before and after transmural revascularization*. *Circulation*, 1999; 100[suppl II]:II-134-II138.
33. Kaufmann PA, Gnechchi-Ruscione T, Yap JT, **Rimoldi O**, Camici PG *Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with oxygen-15 labeled water and PET*. *J Nuc Med*, 1999;40(11):1848-56.
34. Piccini P, Brooks D, Bjorklund A, Gunn R, Grasby PM, **Rimoldi O**, Rehncrona S, Lindvall O: *Dopamine release from nigral transplants visualized in vivo in Parkinson's disease*. *Nature Neuroscience*, 1999; 2 (12):1137-1140.
35. **Rimoldi O** and Camici PG *PET measurement of the coronary flow reserve and microcirculatory function*. *Herz*, 1999; 24 (7):522-30.
36. Barnes E, Baker CS, Dutka DP, **Rimoldi O**, Rinaldi CA, Nihoyannopoulos P, Camici PG, Hall RJ. *Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia*. *Heart*. 2000;83(3):283-9.
37. **Rimoldi O**, Spyrou N, Foale R, Hackett DR, Gregorini L, Camici PG: *Limitation of coronary reserve after successful angioplasty is prevented by oral pretreatment with an α_1 -adrenergic antagonist*. *J Cardiovasc Pharmacol*. 2000;36(3):310-5.
38. Pike VW, Law MP, Osman S, Davenport RJ, **Rimoldi O**, Giardina D, Camici PG. *Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors*. *Pharm Acta Helv*. 2000;74(2-3):191-200. Review.
39. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, Indolfi C, **Rimoldi O**. *alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans*. *Circulation*. 2000 Feb 15;101(6):689-94. Review.
40. Law MP, Osman S, Pike VW, Davenport RJ, Cunningham VJ, **Rimoldi O**, Rhodes CG, Giardina D, Camici PG. *Evaluation of [¹¹C]GB67, a novel radioligand for imaging myocardial alpha₁-adrenoceptors with positron emission tomography*. *Eur J Nucl Med*. 2000;27(1):7-17.
- Porta A, Baselli G, **Rimoldi O**, Malliani A, Pagani M. *Assessing baroreflex gain from spontaneous variability in conscious dogs: role of causality and respiration*. *Am J Physiol Heart Circ Physiol*. 2000;279(5):H2558-67.
41. Chareonthaitawee P, Kaufmann P, **Rimoldi O**, Camici PG: *Heterogeneity of Resting and Hyperemic Myocardial Blood Flow in Healthy Humans*. *Cardiovasc. Res*. 2001 Apr; 50 (1):151-61.
42. Baker CSR, Frost MT, **Rimoldi O**, Moore B, Halliwell B, Polak JM, Camici PG, Hall RJC: *Repetitive myocardial stunning in pigs is associated with an increased formation of reactive nitrogen species*. *Heart*. 2002;87: 77-8.
43. Rajappan K, **Rimoldi OE***, Dutka DP, Ariff B, Pennell DJ, Sheridan DJ, Camici PG: *Mechanisms of coronary microcirculatory dysfunction in patients*

with aortic stenosis and angiographically normal coronary arteries. Circulation 2002; 105: 470-476.

* joint first author

44. Chareonthaitawee P, Schaefer K, Baker CSR, Turkheimer F, Yacoub M, Bonser RS, Iozzo P, Camici PG, **Rimoldi O**: *Infarct size assessed by positron emission tomography and [¹⁸F]2-fluoro-2-deoxy-D-glucose: a new absolute threshold technique. Eur J Nucl Med.* 2002 29(2):203-15.

45. Porta A, Furlan R, **Rimoldi O**, Pagani M, Malliani A, van de Borne, P. *Quantifying the strength of the linear causal coupling in closed loop interacting cardiovascular variability signals. Biol Cybern* 2002; 86 (3):241-51.

46. Schaefer KP, Camici PG, Bloomfield PM, Spinks TJ, Rhodes CG, Law MP, Baker CSR, **Rimoldi O**: *Absolute quantification of myocardial blood flow with [¹⁵O]-water and positron emission tomography using the ECAT EXACT3D: experimental validation. J Nucl Med* 2002 43(8):1031-40.

47. Baker C. S., Dutka D. P., Pagano D., **Rimoldi O.**, Pitt M., Hall R. J., Polak J. M., Bonser R. S., Camici P. G. *Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium. Basic Res Cardiol* 2002; 97(5): p. 409-15.

48. Iozzo P., Chareonthaitawee P., **Rimoldi O.**, Betteridge D. J., Camici P. G., Ferrannini E. *Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes. Diabetologia* 2002; 45(10): p. 1404-9.

49. Camici PG, **Rimoldi OE**: *Myocardial blood flow in patients with hibernating myocardium. Cardiovasc Res* 2003; 57: 302-311.

50. Baker CS, Kumar S, **Rimoldi OE**. *Effects of brief ischemia and reperfusion on the myocardium and the role of nitric oxide. Heart Fail Rev.* 2003;8(2):127-41.

51. Camici PG and **Rimoldi O**: *Pathophysiology and diagnosis of hibernating myocardium in patients with post-ischemic heart failure: the contribution of PET. Annals of Nuclear Medicine* 2003; 17(5):341-50.

52. Rajappan K, **Rimoldi OE***, Camici PG, Bellenger NG, Pennell DJ, Sheridan DJ: *Factors Influencing Alterations in Coronary Microcirculatory Function in Patients with Aortic Stenosis After Valve Replacement. Circulation* 2003; 107: 3170-3175.

* joint first author

53. **Rimoldi OE** and Camici PG: *Major Achievements in Nuclear Cardiology VIII: Positron emission tomography for quantitation of myocardial perfusion J Nucl Cardiol* 2004; 11(4): 482-490.

54. Depre C, Kim S, John AS, Huang YH, **Rimoldi OE**, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG and Vatner SF: *Program of cell survival underlying human and experimental hibernating myocardium. Circ Res*, 2004; 95: 433-440.

55. Kaufmann PA, **Rimoldi O**, Gnecci-Ruscione T, Bonser RS, Luscher TF, Camici PG: *Systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans. Circulation* 2004; 110: 1431-1436.

56. Pavese N, **Rimoldi O**, Gerhard A, Brooks DJ, Piccini P. *Cardiovascular effects of methamphetamine in Parkinson's disease patients*. *Mov Disord*. 2004;19(3):298-303.
57. Camici PG, **Rimoldi O**: *The contribution of hibernation to heart failure*. *Annals of Medicine* 2004; 36: 440-447.
58. Kies P, Wichter T, Schäfers M, Paul M, Schäfers KP, Eckardt L, Stegger L, Schulze-Bahr E, **Rimoldi O**, Breithardt G, Schober O, Camici PG: *Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome*. *Circulation* 2004; 110:19: 3017-22.
59. Tansley P, Yacoub M, **Rimoldi O**, Birks E, Hardy J, Hipkin M, Bowles C, Kindler H, Dutka D, Paolo Camici PG: *The effect of left ventricular assist device combination therapy on myocardial blood flow in patients with end stage dilated cardiomyopathy*. *J Heart Lung Transplantation* 2004; 23(11):1283-9.
60. Jagathesan, R, Kaufmann PA, Rosen SD, **Rimoldi O**, Turkheimer F, Camici PG. *Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease*. *J Nucl Med*, 2005. **46**(2): p. 212-9.
61. **Rimoldi O**, Schafers KP, Boellaard R, Turkheimer F, Stegger L, Law MP, Lammerstma AA, and Camici PG. *Quantification of Subendocardial and Subepicardial Blood Flow Using 15O-Labeled Water and PET: Experimental Validation*. *J Nucl Med*. Jan 2006;47(1):163-172.
62. Elliott PM, Kindler H, Shah JS, Sachdev B, **Rimoldi OE**, Thaman R, Tome MT, McKenna WJ, Lee P, and Camici PG. *Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A*. *Heart* 92: 357-360, 2006.
63. **Rimoldi OE**, Drake-Holland AJ, Noble MI, and Camici PG. *Basal and hyperaemic myocardial blood flow in regionally denervated canine hearts: an in vivo study with positron emission tomography*. *Eur J Nucl Med Mol Imaging* 34: 197-205, 2007.
64. John AS, Mongillo M, Depre C, Khan MT, **Rimoldi OE**, Pepper JR, Dreyfus GD, Pennell DJ, Camici PG. *Pre- and post-synaptic sympathetic function in human hibernating myocardium*. *Eur J Nucl Med Mol Imaging*. 2007; 34(12):1973-80.
65. Kaufmann PA, **Rimoldi OE**, Gneccchi-Ruscione T, Luscher TF, Camici PG. *Systemic nitric oxide synthase inhibition improves coronary flow reserve to adenosine in patients with significant stenoses*. *Am J Physiol Heart Circ Physiol*. 2007;293:H2178-2182.
66. Knaapen P, Germans T, Camici PG, Rimoldi OE, ten Cate FJ, ten Berg JM, Dijkmans PA, Boellaard R, van Dockum WG, Gotte MJ, Twisk JW, van Rossum AC, Lammertsma AA, Visser FC. *Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy*. *Am J Physiol Heart Circ Physiol*. 2008;294:H986-993.
67. Rota M, Hosoda T, De Angelis A, Arcarese ML, Esposito G, Rizzi R, Tillmanns J, Tugal D, Musso E, **Rimoldi O**, Bearzi C, Urbanek K, Anversa P, Leri A, Kajstura J. *The Young Mouse Heart Is Composed of Myocytes Heterogeneous in Age and Function* *Circ Res* 2007 101(4):323-5.
68. Camici PG, Prasad SK and **Rimoldi O** *Stunning, hibernation and assessment of myocardial viability*. *Circulation*. 2008;117:103-114.
69. Park-Holohan SJ, Asselin MC, Turton DR, Williams SL, Hume SP, Camici PG, **Rimoldi O**. *Quantification of [11C]GB67 binding to cardiac alpha1-*

adrenoceptors with positron emission tomography: validation in pigs. *Eur J Nucl Med Mol Imaging*. 2008;35:1624-35.

70. Camici PG, **Rimoldi OE**. *The Clinical Value of Myocardial Blood Flow Measurement*. *J Nucl Med*. 2009; 50 (7): 1076-87.

71. Kumar S, Hall RJ, Mani AR, Moore KP, Camici PG, **Rimoldi OE**, Williams AJ, Macleod KT. *Myocardial stunning is associated with impaired calcium uptake by sarcoplasmic reticulum*. *Biochem Biophys Res Commun*. 2009 Sep 11;387(1):77-82.

72. Garcia D, Camici PG, Durand LG, Rajappan K, Gaillard E, **Rimoldi OE**, Pibarot P. *Impairment of coronary flow reserve in aortic stenosis*. *J Appl Physiol*. 2009;106:113-121.

73. D'Alessandro DA, Kajstura J, Hosoda T, Gatti A, Bello R, Mosna F, Bardelli S, Zheng H, D'Amario D, Padin-Iruegas ME, Carvalho AB, Rota M, Zembala MO, Stern D, **Rimoldi O**, Urbanek K, Michler RE, Leri A, Anversa P. *Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart*. *Circ Res*. 2009;105(11):1128-1140.

74. Karamitsos TD, Recio-Mayoral A, Arnold JR, Leccisotti I, Bhamra-Ariza P, Robson M, **Rimoldi OE**, Camici PG, Neubauer S, Selvanayagam JB. *Relationship between regional perfusion and oxygenation in patients with coronary artery disease*. *Heart* 2009;**95**:A17-A18.

75. Pugliese F, Lamare F, Bhamra-Ariza P, **Rimoldi OE**, Mason J, Camici PG. *Detection of vascular inflammation by PET/CT imaging with 11C-PK 11195*. *European Heart Journal Supplements* 2009;**11**(B):S76-S77.

76. Camici PG, **Rimoldi OE**. *A novel (18)F-labeled tracer for the quantification of myocardial blood flow and infarct size with positron-emission tomography: another way to avoid the need of an on-site cyclotron*. *Circ Cardiovasc Imaging* 2009;**2**(2):75-6.

77. Ammirati E, **Rimoldi OE**, Camici PG. *Is there evidence supporting coronary revascularization in patients with left ventricular systolic dysfunction?* *Circ J*. 2010;**75**(1):3-10.

78. Gaemperli O, Boyle JJ, **Rimoldi OE**, Mason JC, Camici PG. *Molecular imaging of vascular inflammation*. *Eur J Nucl Med Mol Imaging*. 2010;**37**(6):1236.

79. Gaemperli O, Liga R, Bhamra-Ariza P, **Rimoldi O**. *Nicotine addiction and coronary artery disease: impact of cessation interventions*. *Curr Pharm Des*. 2010;**16**(23):2586-2597.

80. Gaemperli O, Liga R, Spyrou N, Rosen SD, Foale R, Kooner JS, **Rimoldi OE**, Camici PG. *Myocardial beta-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure*. *Eur Heart J*. 2010;**31**(14):1722-1729.

81. Ghosh N, **Rimoldi OE**, Beanlands RS, Camici PG. *Assessment of myocardial ischaemia and viability: role of positron emission tomography*. *Eur Heart J*. 2010;**31**(24):2984-2995.

82. Karamitsos TD, Leccisotti L, Arnold JR, Recio-Mayoral A, Bhamra-Ariza P, Howells RK, Searle N, Robson MD, **Rimoldi OE**, Camici PG, Neubauer S, Selvanayagam JB. *Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography*. *Circ Cardiovasc Imaging*. 2010;**3**(1):32-40.

83. Pugliese F, Gaemperli O, Kinderlerer AR, Lamare F, Shalhoub J, Davies AH, **Rimoldi OE**, Mason JC, Camici PG. *Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography*. J Am Coll Cardiol. 2010;56(8):653-661.
84. Varela-Carver A, Parker H, Kleinert C, **Rimoldi O**. *Adverse effects of cigarette smoke and induction of oxidative stress in cardiomyocytes and vascular endothelium*. Curr Pharm Des. 2010;16(23):2551-2558.
85. Lamare F, Hinz R, Gaemperli O, Pugliese F, Mason JC, Spinks T, Camici PG, **Rimoldi OE**. *Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT*. J Nucl Med. 2011;52(1):33-39.
86. Ammirati E, **Rimoldi OE**, Camici PG. *Myocardial viability in ischemic left ventricular dysfunction*. N Engl J Med. 2011;365:471; author reply 472-473.
87. Camici PG, I Olivotto, and **OE Rimoldi**. *The coronary circulation and blood flow in left ventricular hypertrophy*. J Mol Cell Cardiol. 2012; 52, 857-64.
88. Gaemperli O, Shalhoub J, Owen DR, Lamare F, Johansson S, Fouladi N, Davies AH, **Rimoldi OE***, Camici PG. *Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography*. Eur Heart J. 2012;33:1902-10. *Joint Senior Author.
89. Camici PG, Olivotto I, **Rimoldi OE**. *The coronary circulation and blood flow in left ventricular hypertrophy*. J Mol Cell Cardiol 2012;52(4):857-64.
90. Camici PG, **Rimoldi OE**, Gaemperli O, Libby P. *Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque*. European Heart Journal 2012;33(11):1309-17.
91. Roghi A, Lanza D, Pedrotti P, Milazzo A, **Rimoldi O**, Pedretti S. *Relationship between clinical presenting patterns of acute myocarditis and oedema and late enhancement extension*. Journal of Cardiovascular Magnetic Resonance 2012;14(Suppl 1):185.
92. Arnold JR, Karamitsos TD, Bhamra-Ariza P, Francis JM, Searle N, Robson MD, Howells RK, Choudhury RP, **Rimoldi OE**, Camici PG, Banning AP, Neubauer S, Jerosch-Herold M, Selvanayagam JB. *Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 Tesla*. J Am Coll Cardiol 2012;59(22):1954-64.
93. Ammirati E, Moroni F, Pedrotti P, Scotti I, Magnoni M, Bozzolo EP, Rimoldi OE, Camici PG. *Non-invasive imaging of vascular inflammation*. Front Immunol. 2014;5:399.
94. Camici PG, Rimoldi OE. *Coronary stenosis and transmural perfusion across the left ventricular wall*. Eur Heart J. 2014;35:2058-2059
95. Lamare F, Le Maitre A, Dawood M, Schafers KP, Fernandez P, Rimoldi OE, Visvikis D. *Evaluation of respiratory and cardiac motion correction schemes in dual gated pet/ct cardiac imaging*. Med Phys. 2014;41:072504
96. Rimoldi O, Rosen SD, Camici PG. *The blunting of coronary flow reserve in hypertension with left ventricular hypertrophy is transmural and correlates with systolic blood pressure*. J Hypertens. 2014;32:2465-2471;
97. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, Blankstein R, **Rimoldi O**, Camici PG, Di Carli MF. *Effects of sex on coronary microvascular dysfunction and cardiac outcomes*. Circulation. 2014;129:2518-2527.

98. Camici PG, Rimoldi OE. Coronary stenosis and transmural perfusion across the left ventricular wall. *Eur Heart J*. 2014;35:2058-2059.
99. Camici PG, d'Amati G, **Rimoldi O**. *Coronary microvascular dysfunction: Mechanisms and functional assessment*. *Nat Rev Cardiol*. 2015;12:48-62.
100. Maranta F, Tondi L, Agricola E, Margonato A, **Rimoldi O**, Camici PG. *Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia*. *Basic Res Cardiol*. 2015;110:55
101. Gorla R, **Rimoldi O**, De Cobelli F, Durante A, Pizzicannella J, Camici PG. *An accordion not to be played*. *J Cardiovasc Med (Hagerstown)*. 2015;16 Suppl 2:S81-83.
102. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, Blankstein R, **Rimoldi O**, Camici PG, Di Carli MF. *Response to letter regarding article, "effects of sex on coronary microvascular dysfunction and cardiac outcomes"*. *Circulation*. 2015;131:e376
103. Lazzeroni D, **Rimoldi O**, Camici PG. *From left ventricular hypertrophy to dysfunction and failure*. *Circ J*. 2016;80:555-564
104. Pedrotti P, Vittori C, Facchetti R, Pedretti S, Dellegrottaglie S, Milazzo A, Frigerio M, Cipriani M, Giannattasio C, Roghi A, **Rimoldi O**. *Prognostic impact of late gadolinium enhancement in the risk stratification of heart transplant patients*. *Eur Heart J Cardiovasc Imaging*. 2017;18(2):130-137
105. Ammirati E, Moroni F, Magnoni M, Rocca MA, Messina R, Anzalone N, De Filippis C, Scotti I, Besana F, Spagnolo P, **Rimoldi OE**, Chiesa R, Falini A, Filippi M, Camici PG. *Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients*. *Scientific reports* 2017;7(1):10559.
106. Durante A, Laricchia A, Benedetti G, Esposito A, Margonato A, **Rimoldi O**, De Cobelli F, Colombo A, Camici PG. *Identification of High-Risk Patients After ST-Segment-Elevation Myocardial Infarction: Comparison Between Angiographic and Magnetic Resonance Parameters*. *Circulation. Cardiovascular imaging* 2017;10(6):e005841.
107. Gupta A, Taqueti VR, van de Hoef TP, Bajaj NS, Bravo PE, Murthy VL, Osborne MT, Seidelmann SB, Vita T, Bibbo CF, Harrington M, Hainer J, **Rimoldi O**, Dorbala S, Bhatt DL, Blankstein R, Camici PG, Di Carli MF. *Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease*. *Circulation* 2017;136(24):2325-2336.
108. **Rimoldi O**. *Interconnection of coronary macro- and microcirculation to each other: each component has relations that express all the others*. *European heart journal cardiovascular Imaging* 2017;18(11):1214-1215.
109. Ammirati E, Moroni F, Magnoni M, Busnardo E, Di Terlizzi S, Villa C, Sizzano F, Scotti I, Palini A, Presotto L, Bettinardi V, Spagnolo P, Besana F, Gianolli L, **Rimoldi O**, Camici PG. *Carotid artery plaque uptake of C-11-PK11195 inversely correlates with circulating monocytes and classical CD14(++)CD16(-) monocytes expressing HLA-DR*. *International Journal Of Cardiology. Heart & Vasculature*, 2018 vol. 21, p. 32-35, ISSN: 2352-9067, doi: 10.1016/j.ijcha.2018.09.005
110. **Rimoldi O**, Maranta F. *Microvascular dysfunction in infiltrative cardiomyopathies*. *Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology* 2019;26(1):200-207.

Chapters in books

1. Pagani M, Furlan R, Dell'Orto S, **Rimoldi O**, Pizzinelli P, Lombardi F, Cerutti S, Malliani A: *Beat to beat analysis and high fidelity continuous recording of arterial pressure*. In: Neural Mechanisms and Cardiovascular Disease, B.Lown, A. Malliani, M. Prosdocimi (eds) Fidia Research Series Vol. 5 Liviana Press, Padova, 1986 pp. 209-216
2. Pagani M, **Rimoldi O**, Furlan R, Malliani A. *Neuro-humoral control. in vascular dynamics*. 1988 EDS N. Westerhof D.R. Gross NATO ASI series. Series A: Life Sciences Vol 166:23-35.
3. Pagani M, **Rimoldi O**, Pizzinelli P, Lucini D, Malliani A: *Spectral analysis of cardiovascular variables as a tool to quantify neural cardiovascular control in the laboratory and real life conditions*. Haken H and Koepchen HP (eds.), Rhythms in Physiological Systems, Springer Series in Synergetics 1991;55:103-114
4. Malliani A, Pagani M, Lombardi F, **Rimoldi O**. *Spectral analysis of heart period and arterial pressure variabilities as a tool to explore neural cardiovascular regulation*. In: Spectral analysis of heart rate variability signal. S. Cerutti and G. Minuco Eds. Fondazione Clinica del Lavoro Veruno 1991:115-131.
5. Pagani M, **Rimoldi O**, Malliani A: *Low-frequency components of cardiovascular variabilities as markers of sympathetic modulation*. Current Techniques TiPS 1992;13:50-54
6. Malliani A, Pagani M, Lombardi F, **Rimoldi O**. *Low frequency oscillation of heart rate and arterial pressure variabilities as a marker of sympathetic modulation of cardiovascular function*. In: Blood pressure and Heart rate variability M. Di Rienzo, G. Mancia, G. Parati, A. Pedotti and A.Zanchetti (Eds.), IOS Press 1993:215-229
7. Pagani M, Lucini D, **Rimoldi O**, Furlan R, Piazza S, Biancardi L. *Effects of physical and mental exercise on heart rate variability*. In: Heart rate variability. Malik M, Camm AJ (eds.), Armonk, NY, Futura Publishing Company Inc., 1995 pp. 245-266.
8. Pagani M, **Rimoldi O**, Pagani MR, Pizzinelli P, Lombardi F, Cerutti S, Malliani A. *Sympathetic afferents and neural control of the circulation*. In: From the Heart to Brain. The Psychophysiology of Circulation-Brain Interaction. Vaitl D, Schandry R, (eds.), Peter Lang, Frankfurt, 1995 pp.61-81.

9. Pagani M, Lucini D, **Rimoldi O**, Furlan R, Piazza S, Porta A, Malliani A. *Low and high frequency components of blood pressure variability*. In: Annals of the New York Academy of Sciences. Portaluppi F and Smolensky MH (eds). The New York Academy of Sciences, New York, New York, 1996 Vol 783 pp10-23.
10. Camici P.G., **Rimoldi O**: *The coronary microcirculation and myocardial ischemia*. In: Advanced Imaging in Coronary Artery Disease, Van der Wall et al (eds.) Kluwer Academic Publishers. The Netherlands 1998:101-107.
11. Camici PG, **Rimoldi O**: *Clinical investigation of microcirculation in cardiovascular patients*. In Microcirculation and Cardiovascular Disease. Struijker HAJ and Ambrosio G Eds. Lippincott, Williams and Wilkins, 2000; 127-142.
12. Camici PG, **Rimoldi O**: *The coronary microcirculation and myocardial ischemia*. Cardiac PET Imaging, Kluwer Academic Publishing.
13. Camici PG, Rosen SD, Spinks TJ and **Rimoldi O**: *Positron emission tomography*. In: *Nuclear Medicine in Clinical Diagnosis and Treatment*. Ell PJ and Gambhir SS Eds. 3rd Edition. 2003. Churchill-Livingstone, London 2004; 1075-91.
14. Camici P, **Rimoldi O**. *Myocardial Ischemia and Viability*. In: Cademartiri F, Casolo G, Midiri M, (eds). Cardiac CT in Clinical Practice 2nd ed: Elsevier; 2011.
15. Bengel F, **Rimoldi O**, Camici PG *Nuclear Cardiology (PET and SPECT) – Basic Principles* in ESC Textbook of Cardiovascular Imaging 2nd Edition José Luis Zamorano, Jeroen J. Bax, Frank E. Rademakers and Juhani Knuuti Eds Jan 2015
16. Camici PG, **Rimoldi O**, Crea F Coronary Microvascular Dysfunction. In: (a cura di): James de Lemos Torbjørn Omland, Chronic Coronary Artery Disease 1st Edition A Companion to Braunwald's Heart Disease. vol. 1, p. 55-68, Elsevier, ISBN: 9780323428804; 2017

Citation report for 256 results from All Databases between 1950 and 2019 Go

You searched for: AUTHOR: (Rimoldi, o)
Timespan: All years. Databases: WOS, KJD, MEDLINE, RSCI, SCIELO.
...Less

This report reflects citations to source items indexed within All Databases.

Cattura rettangolare

Export Data: Save to Excel File

